<DOC>
	<DOCNO>NCT02004093</DOCNO>
	<brief_summary>This study evaluate efficacy safety pertuzumab combination carboplatin-based standard chemotherapy patient platinum-sensitive recurrent ovarian cancer . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Evaluate Effect Combination Pertuzumab With Carboplatin-Based Standard Chemotherapy Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histologically confirm ovarian , primary peritoneal , fallopian tube cancer ; 1 previous regimen , must platinumbased ; platinumsensitive disease define progressionfree interval great 6 month completion platinumbased chemotherapy . previous radiotherapy ; previous treatment anticancer vaccine target therapy ; major surgery traumatic injury within 4 week study ; history evidence central nervous system metastasis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>